Becton, Dickinson and Company
BD Announces Organizational Realignment into Five Segments
Summary
Becton Dickinson and Company (BD) has restructured its operational units into five distinct segments, effective October 1, 2025, to better align with the nature of its product and service offerings. This reorganization is expected to facilitate more focused management and clearer segment reporting moving forward. Additionally, BD plans to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, leading to the elimination of the Life Sciences segment from future segment reporting. The filing includes detailed financial data, adjusted for this reorganization, to provide clarity on the financial impact of these changes.
Profitelligence Alerts
Get alerts for BDX
Be first to know when Becton, Dickinson and Company files with the SEC.
Filing Categories
Advertisement
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.
Official SEC Documents
Advertisement